The trial included 198 patients with inadequately controlled acromegaly on maximum approved doses of octreotide LAR or lanreotide Autogel for at least 6 months, regardless of prior surgical status. The primary endpoint of this study was the proportion of patients achieving biochemical control as measured by the mean GH levels of <2.5 mcg/L and normalized insulin-like growth factor I (IGF-1) at 24 weeks.

IGF-1 normalization was achieved by 24.6% and 26.2% of patients taking pasireotide LAR 40 mg and 60 mg, respectively (95% CI, 14.8–36.9; P<0.001 and 95% CI, 16.0–38.5; P<0.001, respectively), and was not achieved by any patients in the control arm (95% CI, 0–5.3).